AQST vs SPRY
AQST: Aquestive Therapeutics develops advanced, non-invasive pharmaceutical delivery technologies and products, with a primary focus on its oral epinephrine prodrug candidates for severe allergic reactions. SPRY: ARS Pharmaceuticals has developed neffy, the first FDA-approved needle-free intranasal epinephrine spray for the emergency treatment of severe allergic reactions.
Side-by-side fundamentals
| Metric | AQST | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $4.08 | $4.18 | |
| Market cap | $512M | $416M | |
| Net margin FY2025, SEC XBRL | -188.1% | -203.3% | AQST higher |
| Operating margin FY2025, SEC XBRL | -159.5% | -212.9% | AQST higher |
| ROE FY2025, SEC XBRL | n/a | -149.9% | |
| ROA FY2025, SEC XBRL | -52.2% | -52.3% | AQST higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 7.73 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -22.6% | -5.5% | SPRY higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | +300.1% | SPRY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.22 | 1.01 | |
| 1-year return as of 2026-10-21 close | -42.0% | -57.8% | AQST higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.